FDA
-
-
-
-
-
-
-
SAB BIO Announces Second Quarter 2024 Financial Results and Provides Company Updates
-
-
-
-
-
-
-
SAB Biotherapeutics Announces Completion of $67.1 Million Financing to Advance Potential Disease-Modifying Treatment for Type 1 Diabetes
-
-
-
-
-
-
-
SAB Biotherapeutics (SABS) Granted Fast Track Designation from FDA for SAB-176
-
-
-
-
-
-
-
SAB Biotherapeutics Advancing Pipeline and Expands into Treatment for C. Diff. as DoD Contract Winds Down
-
-
-
-
-
-
-
SAB Biotherapeutics Reports Positive Phase 2 Virology Data Demonstrating SAB-185 Met Criteria for Advancement to Phase 3 in NIH ACTIV-2 Trial for Treatment of COVID-19
-
-
-
-
-
-
323,573 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

